You have 9 free searches left this month | to do more

niraparib

Niraparib is a drug used to treat Ovarian Cancer, Fallopian Tube Cancer, Ovarian Neoplasms, and other conditions. Niraparib is being actively studied in 90 studies and prior, has been studied in 13.

Top SponsorsTop SitesTop Investigators
Tesaro, Inc.GSK Investigational SiteAlice Ho
Janssen Research & Development, LLCCentre Jean PerrinAntoinette Tan, MD
Massachusetts General HospitalCentre Leon BerardBeihua Kong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Not yet recruiting
  • Ovarian Cancer
  • +2 more
  • (no location specified)
2021-08-10
Aug 10, 2021
E
Withdrawn
  • Advanced Solid Tumor
  • Breast Cancer
  • (no location specified)
2021-06-24
Jun 24, 2021
T
Completed
  • Advanced Solid Tumors
  • Niraparib
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital
2021-10-12
Oct 12, 2021
W
Recruiting
  • HRD
  • +2 more
  • Atlanta, Georgia
    Winship Cancer Institute of Emory University
2022-02-22
Feb 22, 2022
C
Recruiting
  • Metastatic Melanoma
  • Niraparib
  • San Francisco, California
    California Pacific Medical Center Research Institute
2021-10-15
Oct 15, 2021
W
Not yet recruiting
  • Recurrent Small Cell Lung Cancer
  • SBRT
  • +2 more
  • (no location specified)
2021-12-04
Dec 4, 2021
L
Not yet recruiting
  • Epithelial Ovarian Cancer
  • Niraparib
  • (no location specified)
2021-07-23
Jul 23, 2021
M
Recruiting
  • Metastatic Cancer
  • Central Nervous System Cancer
  • Niraparib
  • Boston, Massachusetts
  • +2 more
2022-01-28
Jan 28, 2022
T
Suspended
  • Breast Cancer
  • Niraparib
  • Amsterdam, Netherlands
  • +2 more
2022-03-21
Mar 21, 2022
G
Recruiting
  • Ovarian Neoplasms
  • Breast Neoplasms
  • Niraparib
  • Tucson, Arizona
  • +9 more
2021-10-03
Oct 3, 2021
T
Recruiting
  • Ovarian Cancer
  • Niraparib
  • Hong Kong, Hong Kong
    The University of Hong Kong
2021-09-27
Sep 27, 2021
A
Not yet recruiting
  • Recurrent Ovarian Cancer
  • +2 more
  • (no location specified)
2021-11-16
Nov 16, 2021
T
Recruiting
  • Ovarian Cancer
  • Niraparib
  • Tokyo, Japan
    Takeda Selected Site
2021-10-12
Oct 12, 2021
M
Active, not recruiting
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Niraparib
  • +2 more
  • Boston, Massachusetts
  • +2 more
2021-10-18
Oct 18, 2021
A
Withdrawn
  • Breast Cancer
  • Niraparib
  • +5 more
  • (no location specified)
2021-05-30
May 30, 2021
U
Recruiting
  • ATM Gene Mutation
  • +16 more
  • Niraparib
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
2022-01-26
Jan 26, 2022
A
Active, not recruiting
  • Breast Cancer
  • Ovarian Cancer
  • Sioux Falls, South Dakota
    Avera Cancer Institute
2021-08-24
Aug 24, 2021
M
Recruiting
  • Triple Negative Breast Cancer
  • Residual Disease
  • Niraparib
  • Radiation Therapy
  • Boston, Massachusetts
  • +1 more
2021-10-27
Oct 27, 2021
K
Recruiting
  • Ovarian Cancer
  • +3 more
  • Tucson, Arizona
  • +2 more
2022-02-02
Feb 2, 2022
T
Recruiting
  • Head and Neck Cancer
  • Cincinnati, Ohio
  • +1 more
2021-09-15
Sep 15, 2021
S
Not yet recruiting
  • Platinum-resistant Recurrent Clear Cell Ovarian Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-11-21
Nov 21, 2021
U
Not yet recruiting
  • Recurrent Glioblastoma
  • +3 more
  • Niraparib
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
2022-03-25
Mar 25, 2022
E
Recruiting
  • Advanced Microsatellite Stable Colorectal Carcinoma
  • +5 more
  • Niraparib
  • Panitumumab
  • Atlanta, Georgia
  • +2 more
2021-10-29
Oct 29, 2021
G
Recruiting
  • Solid Tumor, Adult
  • Homologous Recombination Deficiency
  • Washington, District of Columbia
  • +2 more
2021-08-31
Aug 31, 2021